|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 706.70 INR | +0.81% |
|
+1.70% | -5.96% |
| 04-22 | Supriya Lifescience Limited Receives USFDA EIR with VAI Classification for Maharashtra API Facility | CI |
| 04-22 | Supriya Lifescience says US FDA inspects Supriya Lifescience Lote facility | RE |
| Capitalization | 56.88B 603M 513M 469M 443M 823M 833M 5.56B 2.17B 27.31B 2.26B 2.22B 94.41B | P/E ratio 2026 * |
28.4x | P/E ratio 2027 * | 23.1x |
|---|---|---|---|---|---|
| Enterprise value | 56.88B 603M 513M 469M 443M 823M 833M 5.56B 2.17B 27.31B 2.26B 2.22B 94.41B | EV / Sales 2026 * |
6.77x | EV / Sales 2027 * | 5.6x |
| Free-Float |
29.16% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Supriya Lifescience Limited
| 1 day | +0.81% | ||
| 1 week | +1.70% | ||
| Current month | +1.70% | ||
| 1 month | +15.72% | ||
| 3 months | +5.60% | ||
| 6 months | -10.41% | ||
| Current year | -5.96% |
| 1 week | 681.35 |  | 714.8 |
| 1 month | 615.1 | | 717.45 |
| Current year | 545.5 | | 775 |
| 1 year | 545.5 | | 832.4 |
| 3 years | 215.5 | | 842 |
| 5 years | 170.15 | | 842 |
| 10 years | 170.15 | | 842 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 34 | 31/07/2024 | |
| Chief Executive Officer | 35 | 31/07/2024 | |
| Director of Finance/CFO | - | 22/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 25/03/2008 | |
| Director/Board Member | 41 | 31/05/2019 | |
| Director/Board Member | 35 | 31/05/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.81% | +1.70% | +13.38% | +219.85% | 599M | |
| -2.02% | -0.50% | +27.55% | +121.50% | 869B | |
| -0.50% | -2.57% | +42.20% | +36.37% | 536B | |
| -0.84% | -2.58% | +8.45% | +36.49% | 359B | |
| -0.43% | -0.60% | +18.90% | +11.56% | 327B | |
| +0.29% | -1.14% | +31.81% | +12.12% | 281B | |
| +0.04% | -0.40% | +24.44% | +20.99% | 278B | |
| -0.27% | +0.08% | +44.56% | -5.18% | 277B | |
| -1.76% | +4.42% | -32.32% | -49.34% | 206B | |
| +0.16% | +0.13% | +21.40% | +40.76% | 178B | |
| Average | -0.45% | -0.10% | +20.04% | +44.51% | 331.1B | |
| Weighted average by Cap. | -0.83% | +0.24% | +24.46% | +44.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.4B 89.12M 75.72M 69.33M 65.47M 122M 123M 822M 320M 4.03B 334M 327M 13.94B | 10.16B 108M 91.56M 83.83M 79.16M 147M 149M 994M 387M 4.88B 404M 396M 16.86B |
| Net income | 2B 21.23M 18.04M 16.52M 15.6M 28.96M 29.29M 196M 76.27M 961M 79.64M 77.98M 3.32B | 2.46B 26.14M 22.21M 20.34M 19.2M 35.66M 36.07M 241M 93.92M 1.18B 98.06M 96.03M 4.09B |
| Net Debt | - | - |
Employees
515
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/05/26 | 706.70 ₹ | +0.81% | 91,117 |
| 07/05/26 | 701.05 ₹ | -0.46% | 124,410 |
| 06/05/26 | 704.30 ₹ | +1.96% | 157,216 |
| 05/05/26 | 690.75 ₹ | -0.07% | 94,788 |
| 04/05/26 | 691.20 ₹ | -0.53% | 220,896 |
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUPRIYA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition